Document is current

Article History

Accepted: 19 March 2025

First Online: 2 April 2025

Declarations

:

: The authors declare no competing interests.

: In the preparation of this manuscript, we utilized Microsoft Copilot AI to assist in filtering relevant literature and cross-referencing several clinical studies. The AI tool helped identify key studies, emerging therapeutic targets, and ongoing clinical trials pertinent to the topic of Amyotrophic Lateral Sclerosis (ALS). To write this review, the prompts we provided to Copilot were mainly keywords such as "ALS, SOD1G93A, drug combination, drug repurposing, or clinical trials." This helped us identify certain clinical trials that, at first, did not appear among the most relevant in generic searches on PubMed or Google Scholar. This approach ensured a comprehensive review of the available research and facilitated the identification of synergistic and combined therapeutic strategies currently under investigation.The integration of AI in our research process aimed to enhance the accuracy and depth of our analysis by leveraging advanced computational techniques to systematically gather and evaluate the most pertinent information. Also, Copilot-AI-assistance improved the text for readability and style, ensuring that the manuscript is free of errors in grammar, spelling, punctuation and tone.All findings and interpretations presented in this manuscript were critically reviewed and validated by the authors to maintain the highest standards of scholarly integrity. We acknowledge the assistance of Microsoft Copilot AI in the literature review process and affirm that all final decisions and conclusions are the product of the authors' expertise and judgment.